Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
02/2010
02/11/2010US20100034822 Haemophilus Influenzae Type B
02/11/2010US20100034821 Genetic variations associated with tumors
02/11/2010US20100034820 Binding domain-immunoglobulin fusion proteins
02/11/2010US20100034819 Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions on renal disease associated anemia
02/11/2010US20100034818 Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors
02/11/2010US20100034817 Compositions and methods for the treatment of immune related diseases
02/11/2010US20100034816 Treatment of Diabetes by at Least One Epidermal Growth Factor Receptor Specific Antibody or a Derivative Thereof
02/11/2010US20100034815 Method for restoring dendritic cell populations
02/11/2010US20100034814 Compositions and methods for binding lysophosphatidic acid
02/11/2010US20100034813 Substituted pyrazole and triazole compounds as ksp inhibitors
02/11/2010US20100034812 Antibodies Specific for BET V1 and Use Thereof in the Prevention and Treatment of BET V1- Induced Diseases
02/11/2010US20100034811 Therapeutic agents for diseases involving choroidal neovascularization
02/11/2010US20100034810 Pyrimidine derivatives for the prevention of hiv infection
02/11/2010US20100034809 Compositions and Methods for Antibodies Targeting Complement Protein C5
02/11/2010US20100034808 Compositions and methods for preserving cells of the eye
02/11/2010US20100034807 Methods and compositions for discovery of target-specific antibodies using antibody repertoire array (ara)
02/11/2010US20100034806 Methods and Compositons for the Treatment of Marfan Syndrome and Associated Disorders
02/11/2010US20100034805 Kallikrein-inhibitor therapies
02/11/2010US20100034738 Structural Variants of Antibodies for Improved Therapeutic Characteristics
02/11/2010US20100034737 Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use
02/11/2010US20100034736 Identification of cancer stem cells using genetic markers
02/11/2010CA2739318A1 Immunotherapeutic compositions for the treatment of alzheimer's disease
02/11/2010CA2735710A1 Sting (stimulator of interferon genes), a regulator of innate immune responses
02/11/2010CA2733589A1 Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
02/11/2010CA2733529A1 Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof
02/11/2010CA2733497A1 Anti-hepcidin-25 selective antibodies and uses thereof
02/11/2010CA2733461A1 Methods of predicting cancer lethality using replikin counts
02/11/2010CA2733432A1 Treatment of autoimmune and inflammatory disease
02/11/2010CA2733425A1 Vaccines against clostridium difficile and methods of use
02/11/2010CA2733223A1 Pharmaceutical composition for treatment and prevention of cancers
02/11/2010CA2733147A1 Microparticles for use in immunogenic compositions
02/11/2010CA2733075A1 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
02/11/2010CA2733041A1 Effectors of par-2 activation and their use in the modulation of inflammation
02/11/2010CA2732822A1 Infectious bronchitis vaccines derived from ib-qx-like strains
02/11/2010CA2732782A1 Compositions and methods for antibodies targeting complement protein c5
02/11/2010CA2731494A1 Process for the preparation of nicotine-based haptens
02/10/2010EP2151454A2 Platelet-derived growth factor D, DNA coding therefor, and uses thereof
02/10/2010EP2151245A1 Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses
02/10/2010EP2151244A1 Compositions and methods for the diagnosis and treatment of tumor
02/10/2010EP2150624A1 Raccoon poxvirus expressing rabies glycoproteins
02/10/2010EP2150618A1 Il-12 immunotherapy for cancer
02/10/2010EP2150564A2 Antagonists to il-17a, il-17f, and il-23p19 and methods of use
02/10/2010EP2150277A1 Adjuvant combinations of nkt activator, cd40 agonist, and optional antigen, the use through inducing synergistic cellular immunity
02/10/2010EP2150276A1 Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
02/10/2010EP2150274A1 Combinations of gene deletions for live attenuated shigella vaccine strains
02/10/2010EP1354896B1 Monoclonal antibody directed against the human bst2 antigen
02/10/2010EP1278546B1 Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents
02/10/2010EP0910655B1 Vaccines for treatment of lymphoma and leukemia
02/10/2010CN101646458A Combination therapy with angiogenesis inhibitors
02/10/2010CN101646457A Anti-sclerostin antibodies
02/10/2010CN101646456A Methods and compositions for depleting specific cell populations from blood tissues
02/10/2010CN101646455A Therapeutic agent for cancer
02/10/2010CN101646454A Prevention of allergic sensitization
02/10/2010CN101646453A Synbiotic to improve gut microbiota
02/10/2010CN101646452A Probiotics to reduce episodes of diarrhoea in infants born by caesarean section
02/10/2010CN101643732A A gene differentially expressed in breast and bladder cancer and encoded polypeptides
02/10/2010CN101643512A Novel immunoadhesin for the prevention of rhinovirus infection
02/10/2010CN101642567A Aeromonas hydrophila inactivated vaccine and preparation thereof
02/10/2010CN101642566A Preparation method of coccidiosis in chicken obtained by ultraviolet ray and cobalt60gamma-ray irradiation as well as precocity breeding
02/10/2010CN100588708C Anti-SARS vaccine
02/09/2010US7659385 Polynucleotides encoding molecules designated LDCAM
02/09/2010US7659384 Polynucleotides encoding fully human antibodies against human 4-1BB
02/09/2010US7659383 Canine and feline 5T4 polypeptide sequences for use in generating vaccine for prevention and treatment of cell proliferative disorders; veterinary medicine
02/09/2010US7659377 Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer
02/09/2010US7659368 ErbB2 and ErbB3 chimeric heteromultimer adhesins
02/09/2010US7659285 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
02/09/2010US7659251 Ligand for G-protein coupled receptor FPRL2
02/09/2010US7659243 Treatment of ALS and variants thereof consisting of primary lateral sclerosis (PLS) or spinal muscular atrophy (SMA)
02/09/2010US7659117 Immunostimulatory fusion proteins comprising polypeptide antigen for generating protective DC-induced T-cell-mediated immune responses; metastatic cancers
02/09/2010US7659114 Recombinant feline herpesvirus type 1 and polyvalent vaccine using the same
02/09/2010US7659103 Nucleic acid construct containing fulllength genome of human hepatitis C virus, recombinant fulllength virus genome-replicating cells having the nucleic acid construct transferred thereinto and method of producing hepatitis C virus Particle
02/09/2010US7659090 Methods for the separation of streptococcus pneumoniae type 3 polysaccharides
02/09/2010US7659071 Using cell-mediated immune response to e6 and e7 peptides as diagnostic/prognostic indication of recurrence and/or development of cervical intraepithelial neoplasia (CIN)
02/09/2010US7659061 vehicle comprising a modified and an unmodified liquid carrier with ratio of modified to unmodified of 0.00001:99.99999 to less than 0.01:99.99; one to three bioactive agents may be released on a predictable sustained basis.
02/09/2010US7658935 Methods and compositions for stimulating the immune system
02/09/2010US7658934 Chlamydia antigens and protein vaccine
02/09/2010US7658933 Non-cytotoxic protein conjugates
02/09/2010US7658932 removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition and to impair Complement Factor H binding, CD55 and CD59 removal prevent the binding of Complement Factor H; Acquired Immunodeficiency Syndrome
02/09/2010US7658931 Genetically modified cholera toxin (CT-CRM) comprising reduced toxicity and enhanced immunological response for use in preparation of vaccines against parasitic infection
02/09/2010US7658930 Kit for detecting the antibody of HCV and its preparing method
02/09/2010US7658929 Derived from pathogenic microorganisms, useful for vaccination and diagnosis; tuberculosis; detection of CD4+ T lymphocytes recognizing at least one glycopeptide obtained from pathogenic microorganism
02/09/2010US7658928 Using microbiocidal peptides to enhance uptake of cytokines, polylysines, polyarginine and/or aluminum hydroxide in antigen presenting cells; stimulating host protection from invading pathogens
02/09/2010US7658927 Materials and methods for immunizing against FIV infection
02/09/2010US7658926 Autologous T-cell vaccines materials and methods
02/09/2010US7658925 Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof
02/09/2010US7658923 Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26
02/09/2010US7658922 Monoclonal antibodies, hybridoma cell lines, methods and kits for detecting phytase
02/09/2010US7658921 Molecules with extended half-lives, compositions and uses thereof
02/09/2010US7658920 Method of inhibiting the activity of growth factor homolog ZVEGF3
02/09/2010US7658917 A beta aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural beta amyloid peptides when contacted with the peptides.
02/09/2010US7658911 Measuring the level of NR2A and/or NR2B NMDA receptor within three hours after stroke onset; for diagnosing stroke in an emergency room setting
02/09/2010CA2449488C Compositions and methods for treating hyperimmune response in the eye
02/09/2010CA2404945C Taci as an anti-tumor agent
02/09/2010CA2370714C Bacterial ghosts as carrier and targeting vehicles
02/09/2010CA2353612C Boron neutron capture therapy using pre-targeting methods
02/09/2010CA2349875C Dna encoding a growth factor specific for epithelial cells
02/09/2010CA2256532C Immunodominant 120 kda surface-exposed adhesion protein genes of ehrlichia chaffeensis
02/04/2010WO2010014913A1 Toll-like receptor agonist formulations and their use
02/04/2010WO2010014888A2 Methods of enhancing opsonophagocytosis in response to a pathogen
02/04/2010WO2010014854A2 Antibodies that neutralize botulinum neurotoxins
1 ... 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 ... 1823